Hongwei Holly Yin, Ph.D.
Research Professor, High Throughput Screening Core
Academic Appointments
- Director, High Throughput Screening Core Facility
Location
Duarte Cancer Center
1500 East Duarte Road
Duarte, CA 91010
Duarte, CA 91010
Education & Experience
2001, Ph.D., Molecular Biology and Genetics, Cornell University, Ithaca, New York
1995, B.S., Chemistry, Peking University, Beijing, China
2001-2004, Institute Fellow and Postdoctoral Associate, Department of Lead Discovery, Genomics Institute of the Novartis Research Foundation, San Diego, California
2022-present, Director, High Throughput Screening Core Facility, City of Hope, Duarte, California
2017-present, Associate Research Professor, Department of Pathology, City of Hope, Duarte, California
2016-2017, Staff Scientist, Department of Pathology, City of Hope, Duarte, California
2005-2016, Assistant Professor, Head of Cellular Genomics Collaborative Center, Cancer and Cell Biology Division, Translational Genomics Research Institute (TGen)
2004-2005, Research Scientist II, Department of Infectious Diseases, Immusol Inc./iTherX Inc.
Awards & Memberships
Awards
2001, Laboratory Product Sales Graduate Student Research Award, Cornell University
2000, Department of Molecular Biology and Genetics Graduate Research Award, Cornell University
Publications
Chen XP, Yin H, Huffaker TC. The yeast spindle pole body component Spc72p interacts with Stu2p and is required for proper microtubule assembly. The Journal of cell biology. 1998;141(5):1169-79. Epub 1998/06/12. PubMed PMID: 9606209; PubMed Central PMCID: PMCPMC2137192.
Yin H, Pruyne D, Huffaker TC, Bretscher A. Myosin V orientates the mitotic spindle in yeast. Nature. 2000;406(6799):1013-5. Epub 2000/09/13. doi: 10.1038/35023024. PubMed PMID: 10984058.
Yin H*, You L*, Pasqualone D, Kopski KM, Huffaker TC. Stu1p is physically associated with beta-tubulin and is required for structural integrity of the mitotic spindle. Molecular biology of the cell. 2002;13(6):1881-92. Epub 2002/06/12. doi: 10.1091/mbc.01-09-0458. PubMed PMID: 12058056; PubMed Central PMCID: PMCPMC117611.
Donaldson KM*, Yin H*, Gekakis N, Supek F, Joazeiro CA. Ubiquitin signals protein trafficking via interaction with a novel ubiquitin binding domain in the membrane fusion regulator, Vps9p. Current biology : CB. 2003;13(3):258-62. Epub 2003/02/08. PubMed PMID: 12573224.
Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, Basu G, Azorsa D, Perkins LM, Braggio E, Fonseca R, Bergsagel PL, Mousses S, Stewart AK. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood. 2010;115(8):1594-604. Epub 2009/12/10. doi: 10.1182/blood-2009-09-243980. PubMed PMID: 19996089; PubMed Central PMCID: PMCPMC2830764.
Harradine KA, Kassner M, Chow D, Aziz M, Von Hoff DD, Baker JB, Yin H, Pelham RJ. Functional genomics reveals diverse cellular processes that modulate tumor cell response to oxaliplatin. Molecular cancer research : MCR. 2011;9(2):173-82. Epub 2010/12/21. doi: 10.1158/1541-7786.mcr-10-0412. PubMed PMID: 21169384.
Zhu YX, Tiedemann R, Shi CX, Yin H, Schmidt JE, Bruins LA, Keats JJ, Braggio E, Sereduk C, Mousses S, Stewart AK. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood. 2011;117(14):3847-57. Epub 2011/02/04. doi: 10.1182/blood-2010-08-304022. PubMed PMID: 21289309; PubMed Central PMCID: PMCPMC3083298.
Garand C, Guay D, Sereduk C, Chow D, Tsofack SP, Langlois M, Perreault E, Yin HH*, Lebel M*. An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells. Cancer science. 2011;102(7):1410-7. Epub 2011/04/07. doi: 10.1111/j.1349-7006.2011.01948.x. PubMed PMID: 21466612.
Tsofack SP, Garand C, Sereduk C, Chow D, Aziz M, Guay D, Yin HH, Lebel M. NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines. Molecular cancer. 2011;10:145. Epub 2011/11/29. doi: 10.1186/1476-4598-10-145. PubMed PMID: 22118625; PubMed Central PMCID: PMCPMC3240900.
Stark MS, Woods SL, Gartside MG, Bonazzi VF, Dutton-Regester K, Aoude LG, Chow D, Sereduk C, Niemi NM, Tang N, Ellis JJ, Reid J, Zismann V, Tyagi S, Muzny D, Newsham I, Wu Y, Palmer JM, Pollak T, Youngkin D, Brooks BR, Lanagan C, Schmidt CW, Kobe B, MacKeigan JP, Yin H, Brown KM, Gibbs R, Trent J, Hayward NK. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet. 2011;44(2):165-9. Epub 2011/12/27. doi: 10.1038/ng.1041. PubMed PMID: 22197930; PubMed Central PMCID: PMC3267896.
Tiedemann RE, Zhu YX, Schmidt J, Shi CX, Sereduk C, Yin H, Mousses S, Stewart AK. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer research. 2012;72(3):757-68. Epub 2011/12/08. doi: 10.1158/0008-5472.can-11-2781. PubMed PMID: 22147262; PubMed Central PMCID: PMCPMC3622723.
Xie L, Kassner M, Munoz RM, Que QQ, Kiefer J, Zhao Y, Mousses S, Yin HH, Von Hoff DD, Han H. Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Biochemical pharmacology. 2012;83(4):452-61. Epub 2011/11/22. doi: 10.1016/j.bcp.2011.11.005. PubMed PMID: 22100984; PubMed Central PMCID: PMCPMC3265162.
Tibes R, Bogenberger JM, Chaudhuri L, Hagelstrom RT, Chow D, Buechel ME, Gonzales IM, Demuth T, Slack J, Mesa RA, Braggio E, Yin HH, Arora S, Azorsa DO. RNAi screening of the kinome with cytarabine in leukemias. Blood. 2012;119(12):2863-72. Epub 2012/01/24. doi: 10.1182/blood-2011-07-367557. PubMed PMID: 22267604.
Dhruv H, Loftus JC, Narang P, Petit JL, Fameree M, Burton J, Tchegho G, Chow D, Yin H, Al-Abed Y, Berens ME, Tran NL, Meurice N. Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis. The Journal of biological chemistry. 2013;288(45):32261-76. Epub 2013/09/24. doi:
1074/jbc.M113.493536. PubMed PMID: 24056367; PubMed Central PMCID: PMCPMC3820864.
Henderson-Smith A, Chow D, Meechoovet B, Aziz M, Jacobson SA, Shill HA, Sabbagh MN, Caviness JN, Adler CH, Driver-Dunckley ED, Beach TG, Yin H, Dunckley T. SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening. PloS one. 2013;8(10):e77711. Epub 2013/11/10. doi: 10.1371/journal.pone.0077711. PubMed PMID: 24204929; PubMed Central PMCID: PMCPMC3813773.
Evers L, Perez-Mancera PA, Lenkiewicz E, Tang N, Aust D, Knosel T, Rummele P, Holley T, Kassner M, Aziz M, Ramanathan RK, Von Hoff DD, Yin H, Pilarsky C, Barrett MT. STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. Genome medicine. 2014;6(1):9. Epub 2014/02/04. doi: 10.1186/gm526. PubMed PMID: 24484537; PubMed Central PMCID: PMCPMC3971348.
Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, Valdez R, Camoriano J, Fauble V, Tiedemann RE, Qiu YH, Coombes KR, Cardone M, Braggio E, Yin H, Azorsa DO, Mesa RA, Stewart AK, Tibes R. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014;28(8):1657-65. Epub 2014/01/24. doi: 10.1038/leu.2014.44. PubMed PMID: 24451410; PubMed Central PMCID: PMCPMC4131248.
Zhu YX, Yin H, Bruins LA, Shi CX, Jedlowski P, Aziz M, Sereduk C, Kortuem KM, Schmidt JE, Champion M, Braggio E, Keith Stewart A. RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2. Blood. 2015;125(3):483-91. Epub 2014/11/15. doi: 10.1182/blood-2014-05-577130. PubMed PMID: 25395420; PubMed Central PMCID: PMCPMC4296009.
Scortegagna M, Lau E, Zhang T, Feng Y, Sereduk C, Yin H, De SK, Meeth K, Platt JT, Langdon CG, Halaban R, Pellecchia M, Davies MA, Brown K, Stern DF, Bosenberg M, Ronai ZA. PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets. Cancer research. 2015;75(7):1399-412. Epub 2015/02/26. doi: 10.1158/0008-5472.can-14-2785. PubMed PMID: 25712345; PubMed Central PMCID: PMCPMC4383687.
Feng Y, Pinkerton AB, Hulea L, Zhang T, Davies MA, Grotegut S, Cheli Y, Yin H, Lau E, Kim H, De SK, Barile E, Pellecchia M, Bosenberg M, Li JL, James B, Hassig CA, Brown KM, Topisirovic I, Ronai ZA. SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex. Cancer research. 2015;75(24):5211-8. Epub 2015/11/26. doi: 10.1158/0008-5472.can-15-0885. PubMed PMID: 26603897; PubMed Central PMCID: PMCPMC4681635.
Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, Samatar AA, Maitra A, Wennerberg K, Petricoin EF, 3rd, Yin HH, Nelkin B, Cox AD, Yeh JJ, Der CJ. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer cell. 2016;29(1):75-89. Epub 2016/01/05. doi: 10.1016/j.ccell.2015.11.011. PubMed PMID: 26725216; PubMed Central PMCID: PMCPMC4816652.
Kim N, Cho A, Watanabe H, Choi YL, Aziz M, Kassner M, Joung JG, Park AK, Francis JM, Bae JS, Ahn SM, Kim KM, Park JO, Park WY, Ahn MJ, Park K, Koo J, Yin HH, Cho J. Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. Oncotarget. 2016;7(12):13797-809. Epub 2016/02/18. doi: 10.18632/oncotarget.7318. PubMed PMID: 26883194; PubMed Central PMCID: PMCPMC4924679.
Kang HJ, Cui Y, Yin H, Scheid A, Hendricks WP, Schmidt J, Sekulic A, Kong D, Trent JM, Gokhale V, Mao H, Hurley LH. A Pharmacological Chaperone Molecule Induces Cancer Cell Death by Restoring Tertiary DNA Structures in Mutant hTERT Promoters. Journal of the American Chemical Society. 2016. Epub 2016/09/20. doi: 10.1021/jacs.6b07598. PubMed PMID: 27643954.
Roos A, Dhruv HD, Mathews IT, Inge LJ, Tuncali S, Hartman LK, Chow D, Millard N, Yin HH, Kloss J, Loftus JC, Winkles JA, Berens ME, Tran NL. Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells. Oncotarget. 2017;8(7):12234-46. Epub 2017/01/20. doi: 10.18632/oncotarget.14685. PubMed PMID: 28103571; PubMed Central PMCID: PMCPMC5355340.
Ding KF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ. Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responses. Oncotarget. 2017;8(17):27786-99. doi: 10.18632/oncotarget.15347. PubMed PMID: 28212541; PubMed Central PMCID: PMC5438608.
Yuan Y, Kos FJ, He TF, Yin HH, Li M, Hardwick N, Zurcher K, Schmolze D, Lee P, Pillai RK, Chung V, Diamond DJ. Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab. Oncoimmunology. 2017;6(12):e1363138. Epub 2017/12/07. doi: 10.1080/2162402x.2017.1363138. PubMed PMID: 29209571; PubMed Central PMCID: PMCPMC5706612.
Ding KF, Petricoin EF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ. Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis. Oncotarget. 2018;9(4):5044-57. doi: 10.18632/oncotarget.23495. PubMed PMID: 29435161; PubMed Central PMCID: PMC5797032.
Zhao X, Zhang Z, Moreira D, Su YL, Won H, Adamus T, Dong Z, Liang Y, Yin HH, Swiderski P, Pillai RK, Kwak L, Forman S, Kortylewski M. B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Molecular therapy : the journal of the American Society of Gene Therapy. 2018. doi: 10.1016/j.ymthe.2018.01.007. PubMed PMID: 29433938.
Lang JD, Hendricks WPD, Orlando KA, Yin H, Kiefer J, Ramos P, Sharma R, Pirrotte P, Raupach EA, Sereduk C, Tang N, Liang WS, Washington M, Facista SJ, Zismann VL, Cousins EM, Major MB, Wang Y, Karnezis AN, Sekulic A, Hass R, Vanderhyden BC, Nair P, Weissman BE, Huntsman DG, Trent JM. Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018. doi: 10.1158/1078-0432.CCR-17-1928. PubMed PMID: 29440177.
Ding KF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ. Network rewiring in cancer: Applications to melanoma cell lines and the cancer genome atlas patients. Frontiers in Genetics 2018 Jul 10;9:228. doi: 10.3389/fgene.2018.00228. PubMed PMID: 30042785
Zhang XH, Nam S, Wu J, Chen CH, Liu X, Li H, McKeithan T, Gong Q, Chan WC, Yin HH, Yuan YC, Pillai R, Querfeld C, Horne D, Chen Y, Rosen ST. Multi-kinase inhibitor with anti-p38r activity in cutaneous T-cell lymphoma. Journal of Investigative Dermatology. 2018 Nov; 138(11):2377-2387. doi: 10.1016/j.jid2018.04.030. PubMed PMID: 29758280.
Lee JS, Yost SE, Blanchard S, Schmolze D, Yin HH, Pillai R, Robinson K, Tang A, Martinez N, Portnow J, Wen W, Yim JH, Brauer HA, Ren Y, Luu T, Mortimer J, Yuan Y. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. Breast cancer research : BCR. 2019;21(1):119. doi: 10.1186/s13058-019-1202-4. PubMed PMID: 31703728; PubMed Central PMCID: PMC6839083.
Wang C, Park J, Ouyang C, Longmate JA, Tajon M, Chao J, Lim D, Sandhu J, Yin HH, Pillai R, Gozo MC, Avalos C, Egelston CA, Lee PP, Fakih M. A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver Metastases. The oncologist. 2019. doi: 10.1634/theoncologist.2019-0924. PubMed PMID: 31857446.
Zhang IY, Zhou H, Liu H, Zhang L, Gao H, Liu S, Song Y, Alizadeh D, Yin HH, Pillai RK, Badie B. Local and Systemic Immune Dysregulation Alters Glioma Growth in Hyperglycemic Mice. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 (Accepted)